The 2019-European Society of Cardiology/European Atherosclerosis Society guidelines for the management of dyslipidemias (Mach et al., 2019), recommended that physicians consider measuring apoB for CVD risk assessment, particularly in patients with HTG, diabetes, obesity, metabolic syndrome, or low levels of LDL-C. Here, APOB is linked to obesity disorder.